Overview

Bayer AG is a global enterprise with core competencies in the Life Science fields of healthcare and agriculture. As a leading pharmaceutical company, Bayer develops and manufactures a wide range of healthcare products. Nexavar, an anticancer drug, is developed under Bayer's pharmaceuticals division.

Therapeutic areas

API / Drug Master Files

Bayer AG holds 28 active (64 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • MOLIDUSTAT SODIUM (MICRONIZED) DRUG SUBSTANCEActive2020-09-10
  • AZELAIC ACID (A)Active2014-06-26
  • RIVAROXABAN (MICRONIZED) DRUG SUBSTANCEActive2008-07-23
  • RIVAROXABAN COATED TABLETS, 10 MGActive2008-07-23
  • EOB-DTPAActive2007-05-14
  • NORGESTRELActive2004-04-16
  • ILOPROSTActive2004-02-18
  • TESTOSTERONE UNDECANOATE 750 MG I.M.Active2003-08-15
  • TESTOSTERONE UNDECANOATEActive2003-08-15
  • TESTOSTERONEActive2000-10-02
  • ETHINYLESTRADIOL-BETA-CYCLODEXTRIN-CLATHRATEActive2000-07-25
  • DIENOGESTActive1999-02-26
  • GADOBUTROLActive1998-07-07
  • DROSPIRENONEActive1996-09-09
  • CIPROFLOXACIN HYDRATED DRUG SUBSTANCEActive1993-07-13

Showing 15 of 64 Drug Master Files.

FDA compliance signals

19 FDA enforcement records linked to this company.

  • 4832020-07-27

    Written procedures fail to include

  • 4832020-07-27

    Prevention of cross contamination, mix-ups

  • 4832020-07-27

    Scientifically sound laboratory controls

  • 4832020-07-27

    Written record of investigation incomplete

  • 4832020-07-27

    Control procedures to monitor and validate performance

  • 4832019-09-24

    Cleaning System

  • 4832019-09-24

    Top/Middle/Bottom container sampling

  • 4832019-09-24

    Written procedures not established/followed

  • 4832019-03-22

    Identification of containers, lines, equipment

  • 4832019-03-22

    Following/documenting laboratory controls

  • 4832019-03-22

    Prepared for each batch, include complete information

  • 4832019-03-22

    Labels and labeling stored separately

  • 4832019-03-22

    Written procedures fail to include

  • 4832019-03-22

    Control procedures to monitor and validate performance

  • warning_letter2017-11-14

    FDA Warning Letter (drug product)

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.